Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCSRT.L Regulatory News (CSRT)

  • There is currently no data for CSRT

Voke® (DEV200) update

3 Jan 2017 07:00

RNS Number : 1264T
Consort Medical PLC
03 January 2017
 

 

Consort Medical plc

 

03 January 2017

 

Voke® (DEV200) update

 

Consort Medical plc ("Consort Medical") (LSE: CSRT) today announces that Nicovations Limited ("Nicovations"), a wholly-owned subsidiary of British American Tobacco plc ("BAT"), has served termination notices for all Supply Agreements with Bespak Europe Limited ("Bespak"), a Consort Medical subsidiary, for Voke®. Termination is effective immediately.

 

· Nicovations has terminated all supply agreements with Bespak for Voke, an MHRA approved nicotine inhaler for harm reduction in smoking

· Bespak remains in a constructive dialogue with Kind Consumer and Nicovations over the future of the Voke programme

· Voke is one of 16 programmes in Bespak's growing development pipeline and Consort Medical's Board at this time does not believe that the Termination materially impacts their expectations for the Group's underlying trading performance for the current financial year

 

Nicovations has terminated the Supply Agreements on the basis of lack of commercial launch of Voke before 31 December 2016, which is a termination right provided for in the Supply Agreements that Nicovation has chosen to invoke.

 

Voke, one of 16 programmes in Bespak's development pipeline, was designed by Kind Consumer, a developer of innovative, medically-authorised products, for licensing into consumer and pharmaceutical markets. The distribution rights to the product were licensed by Kind Consumer to Nicovations and, in relation to this licence agreement, in 2011 Nicovations also entered into separate Supply Agreements with Bespak. The agreements cover the build, manufacturing and supply of the filled Voke devices and associated valves.

 

Bespak remains in a constructive dialogue with Kind Consumer and Nicovations over the future supply of the Voke nicotine inhaler which addresses a fast growing multi-billion dollar market.

 

With a robust financial position and a strong development pipeline, the board of directors of Consort Medical at this time does not believe that the termination of the Supply Agreements materially impacts their expectations for Consort Medical Group's underlying trading performance for the current financial year ending 30 April 2017.

 

Jonathan Glenn, Chief Executive Officer of Consort Medical, commented:

 

"Our recent interim financial results highlighted the underlying strength in Bespak and Aesica and the momentum emanating from the growing and diverse pipeline portfolio of significant development programmes. Therefore, while we are naturally disappointed in the loss of the Supply Agreements for Voke to Nicovations, we continue our dialogue with Kind Consumer and with Nicovations on the future of the programme and we remain highly confident in the robustness of the remainder of our business and our prospects for the future".

 

- Ends -

 

 

Enquiries:

 

Consort Medical

Tel: +44 1442 867920

Jonathan Glenn - Chief Executive Officer

FTI Consulting

Tel: +44 20 3727 1000

Ben Atwell / Simon Conway

 

 

Notes:

 

Market Abuse Regulations (MAR)

This announcement contains inside information.

 

About Consort Medical

 

Consort Medical plc is a leading, global, single source drug and delivery device company (CDMO). We are at the leading edge of innovation and we are committed to investing in patient, clinician and customer driven innovation to create new treatments, new markets and new opportunities.

 

Our businesses

 

Bespak is a global market leader in the manufacture of drug delivery devices for pharmaceutical partner companies, including respiratory, nasal, and injectable products, and the manufacture of devices for the point of care diagnostics market. www.bespak.com.

 

Aesica is a leading provider of finished dose and active pharmaceutical ingredient (API) development and manufacturing services to pharmaceutical partners. www.aesica-pharma.com.

 

We employ more than 2000 people globally of which 1400 are located in the UK. We have UK facilities in King's Lynn, Cambridge, Nelson, Milton Keynes, Cramlington, Queenborough and Hemel Hempstead, German facilities in Monheim and Zwickau and a facility in Pianezza, Italy. Consort Medical is a public company quoted on the premium list of the London Stock Exchange (LSE: CSRT). www.consortmedical.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBTMBTMBIMTTR
Date   Source Headline
18th Jul 201410:21 amRNSDirector/PDMR Shareholding
16th Jul 20147:00 amRNSDirector/PDMR Shareholding
14th Jul 20147:00 amRNSDirectorate Change
1st Jul 20143:46 pmRNSTotal Voting Rights
26th Jun 201410:37 amRNSHolding(s) in Company
24th Jun 20144:15 pmRNSHolding(s) in Company
23rd Jun 20144:28 pmRNSDirector/PDMR Shareholding
23rd Jun 20144:23 pmRNSDirector/PDMR Shareholding
19th Jun 20142:42 pmRNSDirector/PDMR Shareholding
17th Jun 20147:00 amRNSFinal results for the year ended 30 April 2014
4th Jun 20147:00 amRNSDirector Declaration
2nd Jun 20143:16 pmRNSBlocklisting Interim Review
22nd May 20147:00 amRNSChange of Adviser
16th May 201410:39 amRNSHolding(s) in Company
13th May 20147:00 amRNSKing Systems Milestone Payment
14th Apr 20144:58 pmRNSBlocklisting Interim Review
3rd Apr 201411:15 amRNSHolding(s) in Company
1st Apr 20147:00 amRNSDirector Declaration
19th Mar 20147:00 amRNSInterim Management Statement
3rd Mar 20149:00 amRNSTotal Voting Rights
6th Feb 201410:24 amRNSHolding(s) in Company
5th Feb 20142:45 pmRNSHolding(s) in Company
3rd Feb 20147:00 amRNSFDA Approval of Development Programme
28th Jan 20149:43 amRNSHolding(s) in Company
3rd Jan 20149:15 amRNSTotal Voting Rights
31st Dec 20139:34 amRNSHolding(s) in Company
4th Dec 20137:00 amRNSInterim results for the six months to 31/10/13
2nd Dec 20134:15 pmRNSBlocklisting Interim Review
2nd Dec 20134:14 pmRNSTotal Voting Rights
28th Nov 20137:00 amRNSBespak Supply Contract Award
20th Nov 20131:37 pmRNSJefferies 2013 Global Healthcare Conference
15th Nov 20131:54 pmRNSDirector Declaration
4th Nov 20133:37 pmRNSHolding(s) in Company
1st Nov 20137:00 amRNSTotal Voting Rights
31st Oct 201312:21 pmRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
14th Oct 20134:09 pmRNSBlocklisting Interim Review
14th Oct 20133:58 pmRNSHolding(s) in Company
11th Oct 201312:08 pmRNSHolding(s) in Company
10th Oct 20133:32 pmRNSHolding(s) in Company
30th Sep 20133:26 pmRNSTotal Voting Rights
27th Sep 201310:17 amRNSDirector/PDMR Shareholding
6th Sep 20131:51 pmRNSHolding(s) in Company
5th Sep 20131:39 pmRNSDirector/PDMR Shareholding
3rd Sep 201310:15 amRNSResult of AGM
2nd Sep 20137:00 amRNSInterim Management Statement
26th Jul 20132:52 pmRNSPosting of Annual Report and Notice of AGM
24th Jul 20132:43 pmRNSDirector/PDMR Shareholding
22nd Jul 20137:00 amRNSBespak development contract award
27th Jun 201312:27 pmRNSBlocklisting
25th Jun 20134:11 pmRNSBlocklisting Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.